Lauren Averill

Lauren A. Averill is a clinical researcher whose work focuses on the therapeutic and ethical dimensions of psychedelic-assisted interventions for trauma-related and mood disorders. Her portfolio spans investigator-initiated clinical trials and observational studies examining compounds such as ketamine, 5-MeO-DMT and ibogaine, with particular attention to treatment-resistant presentations and populations exposed to military trauma. She has contributed to randomized controlled work on dose-related ketamine effects in veterans with PTSD, translational EEG biomarker studies in late-life treatment-resistant depression, and open-label evaluations of consecutive ibogaine and 5-MeO-DMT–assisted therapy for Special Operations Forces veterans.

Averill also engages with the bio‑psycho‑spiritual and ethical implications of psychedelics in clinical practice and policy; she has published and presented on consent, supportive practices, and implementation considerations for psychedelic therapies, including work on co-occurring alcohol misuse and post-traumatic stress symptoms. Her collaborative publications include partnerships with investigators across academic centres active in psychedelic research and clinical translation, bridging clinical trial methodology, neurophysiological biomarker work, and applied ethics for responsible deployment of psychedelic-assisted care.